Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Clasificación en acciones #4533
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Precio por acción
$27.18
Última sincronización: 2026-07-31
Capitalización bursátil
$3.38B
Cambio (1 día)
-1.41%
Cambio (1 año)
197.05%
País
US
Comercio Tango Therapeutics, Inc. (TNGX)

Categoría

Healthcare
Historial de dividendos de Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. (símbolo bursátil: TNGX) realizó un total de 0 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de Tango Therapeutics, Inc. (TNGX) desde 2026 hasta 2026
Pagos anuales de dividendos
Año Dividendo (ajustado por splits de acciones) Cambiar
Not enough data for the provided dates.
Lista de todos los pagos de dividendos
Año Dividendo Cambiar
Not enough data for the provided dates.
Pagos de dividendos de empresas similares o competidoras
Empresa Número de pagos de dividendos País
0.00%
US
0.00%
US
64.00%
AU
0.00%
CH
0.00%
NL